Jaguar Health Inc. $(JAGX)$ recently announced the establishment of the first study site for its field study of Canalevia-CA1, a prescription drug conditionally approved by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced diarrhea $(CID)$ in dogs. The company aims to achieve full approval for this indication and expand its use to treat general, non-infectious diarrhea in dogs. Jaguar Health is actively seeking potential partners to fund and commercialize crofelemer for general diarrhea treatment in both the U.S. and global markets. The company emphasizes the unmet medical need for such treatments, given the high incidence of diarrhea in dogs and the lack of FDA-approved drugs for general diarrhea management.